Cargando…

Comparative Nonclinical Assessments of the Proposed Biosimilar PF-05280014 and Trastuzumab (Herceptin(®))

BACKGROUND AND OBJECTIVES: Trastuzumab (Herceptin(®)) is a humanized monoclonal antibody (mAb) that binds to the HER2 protein. PF-05280014 is being developed as a potential biosimilar to trastuzumab products marketed in the United States (trastuzumab-US) and European Union (trastuzumab-EU). Nonclini...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hurst, Susan, Ryan, Anne M., Ng, Chee-Keng, McNally, James M., Lorello, Leslie G., Finch, Gregory L., Leach, Michael W., Ploch, Stephen A., Fohey, Josh A., Smolarek, Teresa A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2014
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4176567/ https://www.ncbi.nlm.nih.gov/pubmed/25001079 http://dx.doi.org/10.1007/s40259-014-0103-4

Ejemplares similares

Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin(®)) in patients with HER2-positive metastatic breast cancer
por: Chen, Xiaoying, et al.
Publicado: (2019)

Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin(®)) in patients with HER2‑positive metastatic breast cancer
por: Chen, Xiaoying, et al.
Publicado: (2019)

Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade(®) (Infliximab)
por: Derzi, Mazin, et al.
Publicado: (2016)

Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer
por: Lammers, Philip E., et al.
Publicado: (2018)

PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study
por: Pegram, Mark D., et al.
Publicado: (2018)

Functional and Nonclinical Similarity of ABP 980, a Biosimilar of Trastuzumab
por: Jassem, Shea, et al.
Publicado: (2019)

Long-Term Safety and Effectiveness of PF-05280014 (a Trastuzumab Biosimilar) Treatment in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results of a Randomized, Double-Blind Study
por: Li, Rubi K., et al.
Publicado: (2022)

Drifts in ADCC-related quality attributes of Herceptin®: Impact on development of a trastuzumab biosimilar
por: Kim, Seokkyun, et al.
Publicado: (2017)

Psoriasis Induced by Trastuzumab (Herceptin®)
por: Kim, Dae Hun, et al.
Publicado: (2013)

In silico design, construction and cloning of Trastuzumab humanized monoclonal antibody: A possible biosimilar for Herceptin
por: Akbarzadeh-Sharbaf, Soudabeh, et al.
Publicado: (2012)

Safety survey on infusion reaction and cardiac dysfunction when switching from reference trastuzumab (HERCEPTIN(®)) to biosimilar trastuzumab (Trastuzumab‑NK) in the treatment of HER2‑positive breast cancer
por: Abe, Tomoya, et al.
Publicado: (2023)

Radiation Recall Reaction Induced by Adjuvant Trastuzumab (Herceptin)
por: Chung, Caroline, et al.
Publicado: (2009)

Safety of trastuzumab (Herceptin(®)) during pregnancy: two case reports
por: Goodyer, Matthew J, et al.
Publicado: (2009)

Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase
por: Shpilberg, O, et al.
Publicado: (2013)

TROIKA‐1: A double‐blind, randomized, parallel group, study aimed to demonstrate the equivalent pharmacokinetic profile of HD201, a potential biosimilar candidate to trastuzumab, versus EU‐Herceptin(®) and US‐Herceptin(®) in healthy male subjects
por: Demarchi, Martin, et al.
Publicado: (2021)

The evaluation of left ventricular function for patients being considered for, or receiving Trastuzumab (Herceptin) therapy
por: Fox, K F
Publicado: (2006)

Demonstrating Analytical Similarity of Trastuzumab Biosimilar HLX02 to Herceptin(®) with a Panel of Sensitive and Orthogonal Methods Including a Novel FcγRIIIa Affinity Chromatography Technology
por: Xie, Liqi, et al.
Publicado: (2020)

A randomized, double-blind, parallel-group, single-dose comparative pharmacokinetic study of DRL_TZ, a candidate biosimilar of trastuzumab, with Herceptin(®) (EU) in healthy adult males
por: Lickliter, Jason D., et al.
Publicado: (2021)

Concepts and Challenges of Biosimilars in Breast Cancer: The Emergence of Trastuzumab Biosimilars
por: Uifălean, Alina, et al.
Publicado: (2018)

PF-06438179/GP1111: An Infliximab Biosimilar
por: Al-Salama, Zaina T.
Publicado: (2018)

Plant-Made Trastuzumab (Herceptin) Inhibits HER2/Neu+ Cell Proliferation and Retards Tumor Growth
por: Komarova, Tatiana V., et al.
Publicado: (2011)

The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars
por: Barbier, Liese, et al.
Publicado: (2019)

Physicochemical and Biological Characterization of a Biosimilar Trastuzumab
por: López-Morales, Carlos A., et al.
Publicado: (2015)

Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
por: Waller, Cornelius F., et al.
Publicado: (2021)

Novel Toll-like receptor-4 deficiency attenuates trastuzumab (Herceptin) induced cardiac injury in mice
por: Yousif, Nasser Ghaly, et al.
Publicado: (2011)

Correction to: PF-06438179/GP1111: An Infliximab Biosimilar
por: Al-Salama, Zaina T.
Publicado: (2018)

Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin™) in HER2-overexpressing breast cancer cells
por: Menendez, Javier A, et al.
Publicado: (2007)

A randomized, double-blind, phase III, non-inferiority clinical trial comparing the efficacy and safety of TA4415V (a proposed Trastuzumab biosimilar) and Herceptin (Trastuzumab reference product) in HER2-positive early-stage breast Cancer patients
por: Nodehi, Reza Safaei, et al.
Publicado: (2022)

Crystal Structures of PF-06438179/GP1111, an Infliximab Biosimilar
por: Lerch, Thomas F., et al.
Publicado: (2019)

Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas
por: Martin-Castillo, Begoña, et al.
Publicado: (2015)

Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis
por: Wilson, Florence R., et al.
Publicado: (2018)

Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab
por: Kolberg, Hans-Christian, et al.
Publicado: (2019)

Combination treatment with Grb7 peptide and Doxorubicin or Trastuzumab (Herceptin) results in cooperative cell growth inhibition in breast cancer cells
por: Pero, S C, et al.
Publicado: (2007)

Herceptin® (trastuzumab) in HER2-positive early breast cancer: protocol for a systematic review and cumulative network meta-analysis
por: Wilson, Florence R., et al.
Publicado: (2017)

Development of the Drug Product Formulation of the Bevacizumab Biosimilar PF-06439535 (Bevacizumab-bvzr)
por: Ingram, Rebecca L., et al.
Publicado: (2023)

The role of Herceptin in early breast cancer
por: Subramanian, Ashok, et al.
Publicado: (2008)

Herceptin in clinical use - early 2000
por: Vogel, CL
Publicado: (2000)

Mild hyperthermia influence on Herceptin(®) properties
por: Escoffre, Jean-Michel, et al.
Publicado: (2015)

Monoclonal Antibody and Fusion Protein Biosimilars Across Therapeutic Areas: A Systematic Review of Published Evidence
por: Jacobs, Ira, et al.
Publicado: (2016)

Can we establish a hierarchy among trastuzumab biosimilar candidates?
por: Pivot, Xavier, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_gbrrram7c9rpg8o754in9ad6s7